Maze Therapeutics, Inc. (NASDAQ: MAZE), a clinical-stage biopharmaceutical company with a market capitalization of $569 million, has dosed the first patient in its Phase 2 HORIZON Study of MZE829, ...

A year after guidelines were revised to remove the use of race in eGFR, many labs and pathologists were still relying on the ...

Though highly effective, medications for the prevention of chronic kidney disease progression are under-utilized, emphasizing the need for better use of prognostic tools.

His effort paid off: Tim Andrews, 66, is only the second person known to be living with a pig kidney. Andrews is free from dialysis, Massachusetts General Hospital announced Friday, and recovering so ...

For the second time in less than a year, doctors at Massachusetts General Hospital have transplanted a genetically-edited pig ...

Millions of people worldwide take proton pump inhibitors (PPIs) to relieve heartburn, acid reflux, and gastroesophageal ...

(WIB) – Advances in medical treatment for cardiovascular disease, a leading cause of death in the U.S., have helped patients live longer. But a new report finds that risk factors that lead to heart ...

A personalized neoantigen cancer vaccine generated strong immune responses in renal cell carcinoma patients, leading to ...

The FDA will allow two biotechnology companies to run clinical trials: United Therapeutics and eGenesis. United Therapeutics ...

Patients with chronic kidney disease and those who have had a kidney transplant should avoid high doses of vitamin D, according to an evidence-based consensus document. “Vitamin D deficiency is common ...

GLP-1 medications are renowned for their ability to treat type 2 diabetes and aid weight loss. Now, there's a new benefit to ...